These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Administration of bovine polymerized haemoglobin before and during coronary occlusion reduces infarct size in rabbits. Rempf C; Standl T; Schenke K; Chammas K; Gottschalk A; Burmeister MA; Gottschalk A Br J Anaesth; 2009 Oct; 103(4):496-504. PubMed ID: 19710071 [TBL] [Abstract][Full Text] [Related]
29. [Clinical experience of hemodilution with fluosol-DA (author's transl)]. Fukushima K; Nakamura M; Takemura R Masui; 1981 Jul; 30(7):741-5. PubMed ID: 7321165 [No Abstract] [Full Text] [Related]
30. [Possibility of the use of perfluorochemicals (fluorocarbons) as adjuvants in chemotherapy of cancer]. Kuwamura K; Kokunai T Gan To Kagaku Ryoho; 1982 Jul; 9(7):1256-61. PubMed ID: 7184453 [TBL] [Abstract][Full Text] [Related]
31. Protective effect of perfluorocytylbromide emulsions on a cardioplegic model of reperfusion injury. Zhao L; Smith JR; Eyer CL Proc West Pharmacol Soc; 1992; 35():77-80. PubMed ID: 1502244 [No Abstract] [Full Text] [Related]
32. Rationale for the clinical studies of anemia treated with the perfluorochemical emulsion: Fluosol DA 20%. Tremper KK Prog Clin Biol Res; 1983; 122():307-13. PubMed ID: 6348785 [No Abstract] [Full Text] [Related]
33. [Protective effect of fluosol-DA in acute cerebral ischemia (author's transl)]. Ishikawa R; Peerless SJ; Hunter IG No Shinkei Geka; 1981 Dec; 9(13):1503-8. PubMed ID: 6808409 [TBL] [Abstract][Full Text] [Related]
34. Prevention of ischemia during percutaneous transluminal coronary angioplasty by transcatheter infusion of oxygenated Fluosol DA 20%. Cleman M; Jaffee CC; Wohlgelernter D Circulation; 1986 Sep; 74(3):555-62. PubMed ID: 2943533 [TBL] [Abstract][Full Text] [Related]
35. Fluosol: therapeutic failure in severe anemia. Kale PB; Sklar GE; Wesolowicz LA; DiLisio RE Ann Pharmacother; 1993 Dec; 27(12):1452-4. PubMed ID: 8305774 [TBL] [Abstract][Full Text] [Related]
36. Initial results of a clinical trial of Fluosol-DA 20 percent in acute cerebral ischemia. Swann KW; Ropper AH; Zervas NT Prog Clin Biol Res; 1983; 122():399-404. PubMed ID: 6348787 [TBL] [Abstract][Full Text] [Related]
37. Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188 N.F.), a hemorheological agent that alters neutrophil function. Schaer GL; Hursey TL; Abrahams SL; Buddemeier K; Ennis B; Rodriguez ER; Hubbell JP; Moy J; Parrillo JE Circulation; 1994 Dec; 90(6):2964-75. PubMed ID: 7994844 [TBL] [Abstract][Full Text] [Related]
38. [Pharmacological study and clinical application of fluorocarbon artificial blood]. Zhang RA; Xiong RC; Su BJ Zhonghua Wai Ke Za Zhi; 1985 Jul; 23(7):395-8, 443-4. PubMed ID: 4053861 [No Abstract] [Full Text] [Related]
39. Identification of a time window for therapy to reduce experimental canine myocardial injury: suppression of neutrophil activation during 72 hours of reperfusion. Simpson PJ; Fantone JC; Mickelson JK; Gallagher KP; Lucchesi BR Circ Res; 1988 Dec; 63(6):1070-9. PubMed ID: 2461814 [TBL] [Abstract][Full Text] [Related]
40. Studies of controlled reperfusion after ischemia. XIX. Reperfusate composition: benefits of blood cardioplegia over fluosol DA cardioplegia during regional reperfusion--importance of including blood components in the initial reperfusate. Acar C; Partington MT; Buckberg GD J Thorac Cardiovasc Surg; 1991 Feb; 101(2):284-93. PubMed ID: 1992239 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]